Sleeping Bruxism Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The sleeping bruxism treatment market size is expected to increase from USD 639.56 million in 2025 to USD 683.35 million in 2026 and reach USD 981.95 million by 2031, growing at a CAGR of 7.52% over 2026-2031. This report is Segmented by Treatment Modality (Dental Appliances, Pharmacological and Injectable Therapy, and More), Product Type (Mouth Guards, and More), Patient Type (Adults, Pediatric), End User (Dental Clinics, Hospitals and Multidisciplinary Sleep Centers, and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Sleeping Bruxism Treatment Market Trends and Insights

Rising Diagnosis of Sleep Bruxism with OSA Overlap

The convergence of bruxism and OSA diagnosis inside multidisciplinary sleep workflows is changing how patients enter the sleep bruxism treatment market. Polysomnography data from 345 OSA patients showed that 13.6% had concurrent sleep bruxism, and this subgroup also had higher daytime sleepiness and reduced REM sleep. A separate study of 105 OSA patients found sleep bruxism in 37.1% of cases, and EMG-measured muscle tone produced an AUC of 0.9, which supports the use of wearable EMG for co-screening in sleep settings. This matters commercially because co-diagnosed patients are more likely to move toward dual-use mandibular advancement devices or combined treatment plans instead of single-condition night guards. The literature is also increasingly anchored to AASM-linked diagnostic framing, which suggests sleep medicine standards will continue to shape prescriber behavior in the sleep bruxism treatment market, especially in North America. As these care pathways widen, providers that can address both airway management and tooth protection are likely to capture more of the sleep bruxism treatment market.

Shift Toward Custom Oral Appliances and Digital Dentistry

Digital fabrication is changing the cost, speed, and delivery model of custom oral appliances across the sleep bruxism treatment market. CAD/CAM milling, intraoral scanning, and additive manufacturing are shortening turnaround times and making remote fulfillment models more viable than before. SomnoMed reported that manufacturing investments through 2025 reduced production turnaround from more than 20 days to under 10 days and expanded capacity by more than 40%, which strengthened its ability to convert users from competing products. Panthera’s digitally manufactured nylon appliances carry FDA 510(k) clearance, CE marking, and HCPCS billing support, which improves reimbursement fit and broadens their commercial reach beyond fully self-pay patients. A 2026 systematic review found that digital splints tended to reduce symptom severity more than conventional acrylic splints, although the trials were still limited in size. The result is a sleep bruxism treatment market that is becoming less dependent on the older multi-visit workflow and more responsive to faster custom production.

Underdiagnosis and No Universally Accepted Care Standard

The absence of a universally adopted clinical protocol continues to limit diagnosis and consistent treatment across the sleep bruxism treatment market. An overview of 31 systematic reviews concluded that the evidence base for oral appliances, pharmacological options, and biofeedback remained too heterogeneous to define a clear standard of care. That fragmentation means the same patient can receive different labels and different therapy recommendations depending on whether the first visit is with a general dentist, a sleep physician, or an orofacial pain specialist. Polysomnography remains the gold standard for definitive diagnosis, but cost and access still confine it to specialist settings, so many patients are managed under possible or probable bruxism categories rather than confirmed diagnosis. Reference systems such as ICSD-3 and AASM provide a useful framework, but routine use outside specialist practice remains limited. This slows patient conversion, weakens treatment consistency, and keeps part of the sleep bruxism treatment market below its epidemiological potential.

Other drivers and restraints analyzed in the detailed report include:

• Adult Stress and Anxiety Burden Sustaining Treatment Demand
• Smart Oral Appliances and Biofeedback Moving into Premium Care
• High Out-of-Pocket Costs and Patchy Reimbursement

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Dental appliances held 42.68% of treatment modality revenue in 2025, which kept them at the center of the sleep bruxism treatment market. Custom-fitted night guards, Michigan splints, and mandibular advancement devices remain the core products because they align with familiar first-line practice patterns in established dental systems. Their lead also reflects the established laboratory supply chain that manufactures and distributes these products at scale across clinic networks. Behavioral and physical therapy is projected to grow at an 8.22% CAGR through 2031, making it the fastest-rising treatment approach in the sleep bruxism treatment market. That growth reflects a broader shift toward non-invasive care that can reduce symptom burden without introducing a device-wear barrier for every patient. The sleep bruxism treatment industry is therefore moving toward a more balanced mix of protection, habit management, and supportive care.

The IAPD’s 2024 consensus on pediatric bruxism supports CBT and proprioceptive approaches when psychosocial factors are present, and that position is starting to influence wider protocol design. Pharmacological and injectable therapy remains relevant for patients with masseteric hypertrophy or TMD comorbidity, but the role of botulinum toxin in reducing episode frequency is still debated. A 2024 systematic review of 9 randomized trials found that botulinum toxin improved pain and EMG activity over the first 3 to 16 weeks, but the benefit weakened by 3.5 months. Device-assisted monitoring and biofeedback remain early in commercialization, yet clinical validation is giving that segment a clearer position inside the sleep bruxism treatment industry. Combination therapy is also drawing more interest in premium care settings where patients are willing to pay for broader protocols that unite protection, retraining, and monitoring.

Mouth guards accounted for 45.17% of the sleep bruxism treatment market size in 2025, which made them the largest product category. Soft, hard, and dual-laminate designs remain widely used because they are familiar to prescribers and can be produced across major dental laboratory networks. Hard acrylic Michigan-style guards and flat-plane stabilization splints continue to dominate prescribed use because they provide durable occlusal protection across repeated wear cycles. Dual-laminate and hybrid designs are gaining attention because they try to combine durability with better comfort, and that directly addresses a common adherence barrier. In a German multicenter study, respiratory impairment from a splint reduced adherence by a factor of 10 after insertion, which shows how directly product comfort affects actual use.

Smart and biofeedback devices are projected to grow at a 7.92% CAGR through 2031, making them the fastest-growing product segment in the sleep bruxism treatment market. Their growth reflects the spread of sensor-based monitoring and the appeal of products that do more than passively shield teeth. Sensor-embedded intraoral devices and wearable EMG systems are moving treatment toward measurement, feedback, and remote follow-up rather than simple protection alone. This is one reason the sleep bruxism treatment market is seeing more premium product development, even while conventional guards still dominate volumes. Injectable and oral drug products still serve patients with poor appliance adherence or distinct pain-related needs, but they add incremental revenue rather than replacing appliance-led care across the sleep bruxism treatment market.

Complete Report Scope:

• By Treatment Modality
  • Dental Appliances
    • Mouth Guards
      • Custom-Fitted Night Guards
      • OTC Boil-and-Bite Guards
    • Occlusal Splints
      • Michigan Splints
      • Stabilization Splints
      • Anterior Deprogrammers / NTI-tss
    • Mandibular Advancement and Dual-Use Sleep Appliances
  • Pharmacological and Injectable Therapy
    • Botulinum Toxin Type A
    • Muscle Relaxants
    • Anxiolytics and Sedative-Hypnotics
  • Behavioral and Physical Therapy
    • Cognitive Behavioral Therapy and Stress Management
    • Sleep Hygiene and Relaxation Training
    • Physiotherapy and TMJ Support
  • Device-Assisted Monitoring and Biofeedback
    • EMG Biofeedback Devices
    • Smart Oral Appliances
    • Home Sleep Monitoring Devices
  • Combination Therapy
• By Product Type
  • Mouth Guards
    • Soft
    • Hard
    • Dual-Laminate / Hybrid
  • Occlusal Splints
    • Michigan Splints
    • Flat-Plane Stabilization Splints
    • Anterior Bite Planes / NTI-tss
  • Smart and Biofeedback Devices
    • Headband-Based Biofeedback
    • Sensor-Embedded Oral Appliances
  • Injectable and Oral Drug Products
    • Botulinum Toxin Type A
    • Oral Prescription Drugs
• By Patient Type
  • Adults
    • Younger Adults
    • Middle-Aged Adults
    • Older Adults
  • Pediatric
• By End User
  • Dental Clinics
  • Hospitals and Multidisciplinary Sleep Centers
  • Home Care Settings
  • Specialty Sleep and Neurology Centers
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 37.24% of the sleep bruxism treatment market share in 2025, making it the largest regional segment. The region benefits from relatively strong dental insurance access, broad custom appliance use, and active work on dual-use OSA and bruxism solutions. The United States anchors most regional revenue because it combines a large dental channel with a more developed sleep medicine ecosystem. Diagnosis is also shifting toward multidisciplinary sleep settings, which increases the role of sleep laboratories and sleep physicians in therapy selection. That mix keeps North America commercially mature while still leaving room for premium device innovation and home-based care expansion.

Asia-Pacific is projected to expand at a 9.16% CAGR through 2031, giving it the fastest regional growth within the sleep bruxism treatment market size. Growth across the region is uneven, with Australia contributing more than 80% of SomnoMed’s APAC revenue while also facing competitive and economic pressure in the first half of FY26. China, Japan, and India remain underpenetrated markets where diagnosis is still limited or treatment remains conservative. That leaves a large untreated patient pool across the broader sleep bruxism treatment market. Rising dental infrastructure and consumer health spending continue to support the region’s forward growth path.

Europe remains the second-largest regional segment, and SomnoMed reported 17% revenue growth in Europe to AUD 32.7 million (USD 21.3 million) in the first half of FY26 as reimbursement expanded in France, Sweden, Germany, Norway, and Finland. Germany stands out as a notable demand center because the market combines meaningful patient volume with structured reimbursement and billing channels. The Middle East, Africa, and South America remain smaller today, but both regions are developing gradually as dental infrastructure and awareness improve. Brazil’s clinical research activity and the GCC’s ongoing dental investment support future entry opportunities for premium appliance suppliers. These regions still face cost constraints, which keep treated volumes below the level suggested by underlying epidemiology.

List of Companies Covered in this Report:

• 3D Sleep
• Aesyra SA
• ALIGNERCO
• Brux Night Guard
• Cheeky
• Crown World Dental Lab
• Glidewell
• Grind Relief Pro
• GuardLab
• JS Dental Lab
• National Dentex Labs
• Panthera Dental
• Prestige Consumer Healthcare
• Sentinel Mouthguards
• SleepGuard
• Slow Wave Inc.
• Smile Brilliant
• SomnoMed Limited
• SportingSmiles
• S4S Dental Laboratory
• Procter & Gamble

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support